Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 29;141(3):e202295.
doi: 10.1590/1516-3180.2022.0095.R1.06072022. eCollection 2022.

Prediction and reasons for COVID-19 second dose vaccine hesitation: a cross-sectional study in a municipality of Brazil

Carlos Izaias Sartorão-Filho  1 , Mariana Costa Zoqui  2 , Douglas Otomo Duarte  2 , Edy Alyson Ribeiro  2 , Vinicius César Queiroz Bisetto  2 , Lara Escobar Gavião Cachoni  2 , Ana Luísa Varrone Sartorão  2 , Diogo Coutinho Terribile  2 , Beatriz Balsimelli de Mello  2 , Carlos Izaias Sartorão-Neto  3 , Roberto de Mello  4
Affiliations

Prediction and reasons for COVID-19 second dose vaccine hesitation: a cross-sectional study in a municipality of Brazil

Carlos Izaias Sartorão-Filho et al. Sao Paulo Med J. .

Abstract

Background: Hesitation and refusal to take a second dose of the vaccine for coronavirus disease 19 (COVID-19) are prevalent.

Objectives: We aimed to identify predictive factors for hesitation or refusal and describe groups with higher rates of vaccine hesitancy.

Design and setting: A cross-sectional study in Assis City, Brazil.

Methods: The study included adults who passed the due date for taking the COVID-19 second dose vaccine. Participants were recruited in December 2021 using a mobile-based text message. Sociodemographic and clinical data and reasons for hesitance were collected. The outcome was the attitude towards completing the recommended second dose of the vaccine. Bivariate and multivariate Poisson analyses were performed to determine the adjusted predictors.

Results: Participants between 30-44 years of age had a 2.41 times higher prevalence of hesitation than those aged 18-29 years. In addition, people who had adverse events or previously had COVID-19 had 4.7 and 5.4 times higher prevalences of hesitation, respectively (P value < 0.05).

Conclusion: We found a significant group of adults aged between 30-44 years who refused the second dose of the COVID-19 vaccine. Furthermore, those who reported adverse effects after the first dose and those who had COVID-19 previously were a significant group for refusal.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare no conflict of interest

References

    1. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–228. doi: 10.1038/s41591-020-1124-9. - DOI - PMC - PubMed
    1. MacDonald NE, SAGE Working Group on Vaccine Hesitancy Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015;33(34):4161–4164. doi: 10.1016/j.vaccine.2015.04.036. - DOI - PubMed
    1. Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. Vaccine. 2014;32(19):2150–2159. doi: 10.1016/j.vaccine.2014.01.081. - DOI - PubMed
    1. Lane S, MacDonald NE, Marti M, Dumolard L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015-2017. Vaccine. 2018;36(26):3861–3867. doi: 10.1016/j.vaccine.2018.03.063. - DOI - PMC - PubMed
    1. Hotez PJ. COVID19 meets the antivaccine movement. Microbes Infect. 2020;22(4-5):162–164. doi: 10.1016/j.micinf.2020.05.010. - DOI - PMC - PubMed

Substances